CASE REPORT

Open Access

Digital Ischemia and Necrosis: A Rarely Described Complication of Gemcitabine in Pancreatic Adenocarcinoma

Eiichiro So,¹ Zachary D. Crees,^{2,*} Danielle Crites,³ and Andrea Wang-Gillam³

Abstract

Background: Gemcitabine, alone or in combination with other agents, has become an important part of the standard of care for treatment of both resectable and unresectable/advanced pancreatic adenocarcinoma. Gemcitabine is generally considered to have a favorable toxicity profile, with myelosuppression and hepatotoxicity as the most common adverse effects. There are just two prior published case reports of gemcitabine-associated digital toxicity in the treatment of pancreatic adenocarcinoma, and few case reports when considering all solid tumors.

Presentation: A 70-year-old female developed hand numbness and tingling while receiving nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma. There was initial concern for Raynaud's or nab-paclitaxel-associated neuropathy, thus nab-paclitaxel was discontinued. However, her symptoms progressed to severe pain and her digits became dusky. An extensive evaluation revealed no alternative etiology except gemcitabine-associated digital ischemia (DI). The patient was treated with discontinuation of gemcitabine, and starting nitrates, opiates, calcium-channel blockers, and enoxaparin but eventually progressed to dry gangrene.

Conclusion: Here we report a case of gemcitabine-associated DI, along with a review of the literature. Although a rare complication, DI must be recognized and treated promptly to reduce the likelihood of serious and permanent morbidity.

Keywords: gemcitabine; digital ischemia; pancreatic adenocarcinoma; digital necrosis

Introduction

Gemcitabine as a single agent or in combination therapy is a mainstay treatment for pancreatic adenocarcinoma.^{1,2} Gemcitabine is generally well tolerated, with a favorable toxicity profile.¹ There are case reports of gemcitabine-associated digital ischemia (DI), but there are only two prior case reports in the treatment of pancreatic adenocarcinoma.³⁻⁵ Here we present a case of gemcitabine-associated DI in a patient with pancreatic adenocarcinoma, along with a literature review.

Case Report

A 70-year-old female with metastatic pancreatic adenocarcinoma receiving gemcitabine and nab-paclitaxel

presented to clinic with numbness and tingling in her bilateral hands. Owing to initial concern for nab-paclitaxel-associated neurotoxicity, nab-paclitaxel was discontinued while the patient was continued on gemcitabine (cumulative dose 4160 mg/m²). At 2-week follow-up, the patient reported progressive tenderness, coolness, and purple discoloration of her bilateral index fingers that was initially relieved with warm water immersion. Gemcitabine was promptly discontinued and the patient was admitted for further management. The patient had previously received FOLFOX and then FOLFIRI. She had a history of soleal deep vein thrombosis but no history of rheumatological, connective tissue or peripheral vascular disease. She was a 15-pack/

¹Department of Medicine, Keio University School of Medicine, Tokyo, Japan.

²Department of Medicine, Washington University in Saint Louis, School of Medicine, Saint Louis, Missouri.

³Division of Hematology and Oncology, Department of Medicine, Washington University in Saint Louis, School of Medicine, Saint Louis, Missouri.

*Address correspondence to: Zachary D. Crees, MD, Department of Medicine, Washington University in Saint Louis, School of Medicine, 4901 Forest Park Avenue, Suite 241, Saint Louis, MO 63108, E-mail: zcrees@wustl.edu

FIG. 1. Images of fingers/hands. Red arrows, bilateral index fingers demonstrating cyanosis, digital ischemia, and necrosis. Box, remaining digits demonstrating cyanosis and distal erythema.

year smoker but quit 2 years previously. Her medications included diltiazem, pravastatin, and aspirin.

Upon admission, the patient’s vital signs were within normal limits. Examination revealed bilateral necrotic index fingers (Fig. 1). Basic laboratories revealed leukocytosis, mild anemia, and hypoalbuminemia. The prothrombin time/international normalized ratio, partial thromboplastin time, lupus anticoagulant, anticardiolipin antibody, cryoglobulin S, C3/C4, and extractable nuclear antigen testing were unremarkable. Antinuclear antibody was positive with 1:320 titer and speckled pattern. Echocardiogram showed no evidence of intracardiac thrombi. CT angiography revealed no evidence of systemic emboli. Arterial Doppler studies showed immeasurable digit/arm indices (Fig. 2). Given the negative evaluation for competing etiologies, gemcitabine-associated DI was diagnosed. The patient was managed with gemcitabine discontinuation, along with initiation of calcium-channel blockade, nitrates, and opiates. Therapeutic enoxaparin was also initiated, but was subsequently discontinued because of gastrointestinal bleed. Despite treatment, the patient’s symptoms progressed to dry gangrene of the bilateral index fingers.

FIG. 2. Digit-arm indices. Digit-arm arterial Doppler tracings and indices demonstrating loss of arterial flow to the bilateral index fingers (second digit).

Table 1. Reported Cases of Gemcitabine-Associated Digital Ischemia

Case	Age (y/o)	Sex	Malignancy	Risk factors	Chemotherapy regimen (cumulative dose)	Affected area	Treatment for digital ischemia	Outcome
So et al. (this article)	70	F	Pancreatic	Former tobacco	Gemcitabine (4160 mg/m ²)	Bilateral second digits	Stopped gemcitabine, started calcium-channel blockade, nitrates, opiates, and enoxaparin	Progressed to dry gangrene of the bilateral second digits
Kuhar et al. ⁴	65	M	Pancreatic	Renal impairment	Gemcitabine (4000 mg/m ²)	All digits of both hands	Stopped gemcitabine, started prolonged infusion of a prostacycline analogue, NSAIDs, and opioids	Symptoms resolved in all digits except one, which required amputation
Kuhar et al. ⁴	77	M	Bladder	Tobacco, thrombocytosis and peripheral vascular disease	Gemcitabine (4000 mg/m ²) Cisplatin	Two digits of a right foot	Stopped gemcitabine, started prolonged infusion of a prostacycline analogue, percutaneous luminal angioplasty of right superficial femoral artery	Complete resolution
Zaima et al. ⁵	69	M	Pancreatic	Systemic sclerosis, tobacco, and diabetes	Gemcitabine (7600 mg/m ²)	Multiple fingers and toes	Stopped gemcitabine, started prostaglandins, vasodilators, antiplatelet drugs, antithrombin, bosentan hydrate, and systemic nerve block	Fixed gangrene not requiring amputation of affected digits
Holstein et al. ⁶	70	F	Urothelial	none	Gemcitabine (3000 mg/m ²) Cisplatin or carboplatin	Left fourth, fifth digits and right third, fourth digits	Stopped gemcitabine, started bilateral brachial plexus blockade, intravenous prostacyclin analogue, fractionated heparin, oral corticosteroids, and aspirin	Partial clinical improvement, but with residual fixed gangrene
Vénat-Bouvet et al. ⁷	61	M	Urothelial	Tobacco	Gemcitabine (10,000 mg/m ²) Cisplatin	Second, third digits of bilateral hands	Stopped gemcitabine, started intravenous prostaglandin-E2 analogue	Complete resolution
Clowse and Wigley ⁸	50	F	Lung	Systemic sclerosis	Gemcitabine (unspecified dose) Carboplatin	Right second, fourth, fifth fingers and left third finger	Started calcium channel blocker, prednisolone, cephalexin, gabapentin, and two stellate ganglion blocks	Fixed gangrene requiring amputation of affected digits
Staff et al. ⁹	57	F	Ovarian	Hypercholes-terolemia and carpal tunnel syndrome	Gemcitabine (unspecified dose) Carboplatin	Left second, third, and fourth digits	Started aspirin, calcium channel blocker, low-molecular weight heparin	Partial clinical improvement NOS
Yildiz et al. ¹⁰	59	M	Lung	Tobacco	Gemcitabine (5000 mg/m ²)	Digits of both hands	Stopped gemcitabine, started vasodilator agents, low-molecular weight heparin and aspirin	Partial clinical improvement, NOS
Banach and Williams ¹¹	59	M	Lung	Diabetes	Gemcitabine (unspecified dose)	Right fourth digit, and left first, second digits	Stopped gemcitabine, started intermittent corticosteroids	Fixed gangrene

NOS, not otherwise specified; NSAID, non-steroidal anti-inflammatory drugs.

Discussion

Gemcitabine has been associated with thrombotic vascular complications affecting various organ systems.³ However, DI is a rare adverse effect of gemcitabine likely caused by drug-related microvascular endothelial damage and a relative hypercoagulable state,³ with only case reports to aid clinicians in identifying risk factors, recognizing signs/symptoms, and guiding management decisions. A PubMed search using “digital ischemia/necrosis” and “gemcitabine,” selecting English language articles and also using relevant cases from those articles’ references revealed nine cases of gemcitabine-associated DI (Table 1), with only two cases occurring in pancreatic adenocarcinoma. Risk factors included tobacco use, diabetes, peripheral vascular disease, systemic sclerosis, combination chemotherapy, and cumulative gemcitabine dose >10,000 mg/m².^{2,4–11} Two cases reported favorable outcomes. Kuhar et al. reported using infusion of a prostacycline analogue, NSAIDs, and opioids.⁴ Vénat-Bouvet et al. reported intravenous prostaglandin-E2 analogue alone.¹² In each case, gemcitabine was withdrawn.

In this case, there was no underlying disease. Prior smoking was the only risk factor. The cumulative gemcitabine dose of 4160 mg/m² was lower than previous reports. Given the lack of risk factors and initial suspicion for competing etiologies, gemcitabine was not immediately discontinued. Despite eventual discontinuation of gemcitabine and initiation of vasodilator therapy, the patient suffered irreversible digital necrosis. Therefore, based on variability in risk factors and cumulative dose exposure, clinicians should maintain a high degree of suspicion for gemcitabine-associated DI.

Conclusion

DI is a rare side effect of gemcitabine, which may be attributable to endothelial damage and a hypercoagulable state. There is variability in risk factors, presenting signs/symptoms, and treatment response, creating a diagnostic and treatment dilemma for clinicians. Withdrawing gemcitabine and initiation of prostaglandins and/or alternative vasodilators may be an effective treatment modality.

Author Disclosure Statement

Dr. Andrea Wang-Gillam serves on the advisory boards for Newlink, Pfizer, and Merrimack. The remaining authors have no relevant conflicts of interest or financial disclosures.

References

1. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. *J Clin Oncol*. 1997;15:2403–2413.
2. Ottiano A, Capozzi M, DeDivitiis C, et al. Gemcitabine monotherapy versus Gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials. *Acta Oncologica*. 2017;56:377–383.
3. Dasanu CA. Gemcitabine: vascular toxicity and prothrombotic potential. *Expert Opin Drug Saf*. 2008;7:703–716.
4. Kuhar CG, Mesti T, Zakotnik B. Digital ischemic events related to gemcitabine: Report of two cases and a systematic review. *Radiol Oncol*. 2010;44:257–261.
5. Zaima C, Kanai M, Ishikawa S, et al. A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis. *Jpn J Clin Oncol*. 2011;41:803–806.
6. Holstein A, Bätge R, Egberts EH. Gemcitabine induced digital ischaemia and necrosis. *Eur J Cancer Care (Engl)*. 2010;19:408–409.
7. Vénat-Bouvet L, Ly K, Szelag JC, et al. Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine. *Anticancer Drugs*. 2003;14:829–832.
8. Clowse ME, Wigley FM. Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. *J Rheumatol*. 2003;30:1341–1343.
9. Staff S, Lagerstedt E, Seppänen J, et al. Acute digital ischemia complicating gemcitabine and carboplatin combination chemotherapy for ovarian cancer. *Acta Obstet Gynecol Scand*. 2011;90:1296–1297.
10. Yildiz R, Coskun U, Kaya AO, et al. Digital ischemic changes after gemcitabine therapy in a patient with metastatic non-small-cell lung cancer. *Ann Pharmacother*. 2007;41:901–902.
11. Banach MJ, Williams GA. Purtscher retinopathy and necrotizing vasculitis with gemcitabine therapy. *Arch Ophthalmol*. 2000;118:726–727.
12. Vénat-Bouvet L, Ly K, Szelag JC, et al. Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine. *Anticancer Drugs*. 2003;14:829–832.

Cite this article as: So E, Crees ZD, Crites D, Wang-Gillam A (2017) Digital ischemia and necrosis: a rarely described complication of gemcitabine in pancreatic adenocarcinoma, *Journal of Pancreatic Cancer* 3:1, 49–52, DOI: 10.1089/pancan.2017.0012.

Abbreviations Used

CT = computed tomography
DI = digital ischemia
NSAIDs = non-steroidal anti-inflammatory drugs

Publish in Journal of Pancreatic Cancer

- Immediate, unrestricted online access
- Rigorous peer review
- Compliance with open access mandates
- Authors retain copyright
- Highly indexed
- Targeted email marketing

liebertpub.com/pancan